(Q22251265)

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Neuropathological changes in Down's syndrome hippocampal formation. Effect of age and apolipoprotein E genotype.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Relation between apolipoprotein E genotype, hepatitis B virus status, and thyroid status in a sample of older persons with Down syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Increased low-level chromosome 21 mosaicism in older individuals with Down syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

The presence of isoaspartic acid in beta-amyloid plaques indicates plaque age.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Molecular dating of senile plaques in the brains of individuals with Down syndrome and in aged dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Chromosome missegregation and trisomy 21 mosaicism in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Complement association with neurons and beta-amyloid deposition in the brains of aged individuals with Down Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Oxidation of Abeta and plaque biogenesis in Alzheimer's disease and Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Microglial cells and amyloid beta protein (A beta) deposition; association with A beta 40-containing plaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

The 129 codon polymorphism of the prion protein gene influences earlier cognitive performance in Down syndrome subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Down's syndrome and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

The pathological association between Down syndrome and Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

The neurobiologic consequences of Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Neuronal localization of C1q in preclinical Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Plasminogen activator inhibitor type 1 in adults with Down syndrome and protection against macrovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Trisomy 21 is associated with hypercholesterolemia during intrauterine life

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Intraneuronal Abeta42 accumulation in human brain.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Phospholipid composition and levels are altered in Down syndrome brain

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Statins and the risk of dementia

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

DOES DOWN SYNDROME SUPPORT HOMOCYSTEINE THEORY OF ARTERIOSCLEROSIS?

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Plaques and tangles: searching for primary events in a forest of data.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Life-long overexpression of S100beta in Down's syndrome: implications for Alzheimer pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Beta-amyloid deposition and neurofibrillary tangle association with caspase activation in Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Characteristic developmental expression of amyloid β40, 42 and 43 in patients with Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Clearing the brain's amyloid cobwebs

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Initial sequencing and analysis of the human genome

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Alzheimer dementia in Down's syndrome: the relevance of cognitive ability

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Age-dependent cognitive decline in the APP23 model precedes amyloid deposition.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

A fluid connection: cholesterol and Abeta

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Intracellular accumulation of insoluble, newly synthesized abetan-42 in amyloid precursor protein-transfected cells that have been treated with Abeta1-42.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Rab5-stimulated up-regulation of the endocytic pathway increases intracellular beta-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Abeta production

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

The fetal origins of atherosclerosis: maternal hypercholesterolemia, and cholesterol-lowering or antioxidant treatment during pregnancy influence in utero programming and postnatal susceptibility to atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Down's syndrome: an atheroma-free model?

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Polyol profiles in Down syndrome. myo-Inositol, specifically, is elevated in the cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Apolipoprotein E, Alzheimer's disease and Down's syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Genetic and host factors for dementia in Down's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Influence of the amyloid precursor protein locus on dementia in Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Earlier onset of Alzheimer's disease in men with Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Incidence and temporal patterns of adaptive behavior change in adults with mental retardation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

Intraneuronal Abeta42 accumulation in Down syndrome brain.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NEUROBIOLAGING.2004.08.005

7 January 2021

10.1016/J.NEUROBIOLAGING.2004.08.005

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1676409

1676409

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference